Summit Partners has made a growth investment in Dreampath Diagnostics, a healthcare technology company that digitizes workflows in anatomical pathology laboratories.
Founded in 2012, Dreampath provides patented solutions that automate the archiving and retrieval of tissue samples. The company currently manages over 250 million samples across more than 500 labs in nearly 40 countries, serving hospitals, research institutions, and cancer centers.
Dreampath’s integrated platform, protected by over 80 patents, streamlines lab workflows to prevent patient sample loss, reduce manual errors, and decrease retrieval times. Customers have reported an 83% reduction in time spent archiving tissue samples.
The company has seen rapid, profitable growth with a CAGR exceeding 50% in recent years. Thomas Tarnowski and Jono Pagden have joined Dreampath’s Board of Directors. Dreampath is headquartered in Strasbourg, France, with a U.S. office in New York.
How the funding will be used: This funding will accelerate Dreampath’s global growth, scale its operations, and expand its product portfolio.
KEY QUOTES:
“Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval. Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We’re proud to partner with Summit to help us scale our impact and reach more patients around the world.”
Pablo Jordan, CEO and co-founder of Dreampath Diagnostics
“Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven’t meaningfully evolved in decades. Dreampath’s platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale.”
Thomas Tarnowski, Managing Director at Summit Partners
“We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics. In our view, the company’s first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We’re proud to be their first institutional partner and excited to support the team in scaling their impact globally.”
Jono Pagden, Principal at Summit Partners
